Get The Spin Brief
CRISPRMRIimmunotherapyclinical trialorganoidsbiological age
Pipeline tracker

Casgevy (exagamglogene autotemcel)

Approved/clearedEvidence reviewed by an editor
Casgevy (exagamglogene autotemcel)Vertex Pharmaceuticals and CRISPR Therapeutics · Sickle cell disease and transfusion-dependent beta thalassemia
Approved/cleared · CRISPR/Cas9-edited autologous stem-cell therapyAs of Sep 25, 2026

FDA-approved Dec. 8, 2023 for sickle cell disease (age 12+); CRISPR Therapeutics reported on Aug. 3, 2026 that the FDA extended approval to children 2 years and older.

FDA-approved Dec. 8, 2023 for sickle cell disease (age 12+); CRISPR Therapeutics reported on Aug. 3, 2026 that the FDA extended approval to children 2 years and older.

What this stage means

Approved or cleared applies to specific uses, patient groups and regions. It is not a promise that a treatment works for everyone.

A development stage describes where the evidence stands for one specific use. It does not mean the product works for everyone, is available everywhere, or will succeed commercially.

Development stages, sourced

Elsewhere in the pipeline

Selected therapies and technologies at every stage, from preclinical research to approval. Each stage is dated and linked to a primary source.

Full tracker
Intismeran autogene (V940 / mRNA-4157)Moderna and Merck · High-risk resected melanoma (with pembrolizumab)
Phase 3 · Individualized neoantigen mRNA cancer vaccineAs of Sep 25, 2026
CTX112 (zugocabtagene geleucel)CRISPR Therapeutics · Autoimmune diseases incl. systemic lupus erythematosus and systemic sclerosis
Phase 1 · Allogeneic CRISPR-edited CD19 CAR-T cell therapyAs of Sep 25, 2026
da Vinci 5 surgical system — cardiac indicationsIntuitive Surgical · Cardiac procedures incl. mitral valve repair
Approved/cleared · Robotic-assisted surgical systemAs of Sep 25, 2026
Galleri multi-cancer early detection testGRAIL · Multi-cancer screening in adults 50+
Under review · Cell-free DNA methylation blood test (NGS + machine learning)As of Sep 25, 2026
Optive AI software for Swoop portable MRIHyperfine · Point-of-care brain imaging
Approved/cleared · AI image-reconstruction software for portable ultra-low-field MRIAs of Sep 25, 2026
Hepatocyte epigenetic reprogramming medicineNewLimit · Age-related liver dysfunction
Preclinical · Epigenetic reprogramming therapyAs of Sep 25, 2026

Stages summarise the most advanced publicly documented status for the named use. “Approved” applies to specific indications and regions only. Nothing here is medical or investment advice.